Symbols

LONA

LeonaBio·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LONA

Leonabio, Inc.

Breast cancer+ALS new drug R&D pioneer

Industry

Pharmaceutical

Established Date

03/31/2011

Listing Date

09/18/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.leonabio.com

Security Type

Common stock

Office address

18706 North Creek Parkway, Suite 104, Bothell, Washington 98011

Business

Introduction

LeonaBio, Inc., was incorporated as M3 Biotechnology, Inc., in Washington State on March 31, 2011, and was re-registered as a joint stock company in Delaware on October 27, 2015. The company is an late-stage clinical biopharmaceutical company that develops small drug molecules to restore neuronal health and stop neurodegeneration. Its lead drug candidates, lasofoxifene and ATH-1105, are novel small molecule therapies designed to target devastating diseases for which current treatment options are limited or ineffective. LeonaBio adheres to the pursuit of scientific excellence and patient-centered innovation, and is committed to developing meaningful new therapies for those who need help the most.

Company Financials

EPS

LONA has released its 2025 Q3 earnings. EPS was reported at -1.68, versus the expected -0.13, missing expectations. The chart below visualizes how LONA has performed over recent quarters, highlighting trends in earnings surprises.